An Open-Label, Multicenter, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of RO7296682 in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
Latest Information Update: 16 Jan 2024
At a glance
- Drugs Atezolizumab (Primary) ; Vopikitug (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 11 Jan 2024 Status changed from active, no longer recruiting to completed.
- 19 Oct 2023 Planned End Date changed from 1 Dec 2023 to 31 Jan 2024.
- 19 Oct 2023 Planned primary completion date changed from 1 Dec 2023 to 31 Jan 2024.